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SUMMARY
Objective: To review epidemiological features of bronchopulmonary dysplasia (BPD) 
and its relationship with maternal and neonatal conditions in a neonatal unit. Meth-
ods: Cross-sectional, descriptive and analytical study involving preterm newborns (NBs) 
with a birth weight lower than 1,500 g and gestational age under 37 weeks. Data was 
collected through a review of medical records of these newborns admitted to a neonatal 
unit. Results: The study included 323 newborns with a mean birth weight of 1,161 g 
(± 231 g), gestational age between 24 and 36.5 weeks, with a BPD incidence of 17.6%. 
Among the NBs developing BPD, the mean of days using invasive mechanical ventila-
tion (IMV), non-invasive ventilation (NIMV), and supplemental oxygen was 17.6, 16.2, 
and 46.1 days, respectively, with a time significantly longer for those NBs developing 
BPD (p < 0.001). BPD occurred significantly more often in NBs with a patent ductus 
arteriosus (PDA). Conclusion: BPD incidence in this study was similar to that found in 
the literature. No BPD association with maternal infection and antenatal corticosteroid 
use was found. NBs receiving exogenous surfactant had a higher BPD incidence because 
they had lower BW and GA. Concomitant occurrence of PDA and BPD is associated 
with staying longer on IMV, NIMV and supplemental oxygen.
Keywords: Bronchopulmonary dysplasia; premature newborns; mechanical ventilation; 
oxygen therapy; risk factors.
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INTRODUCTION
When firstly described by Northway in 1967, bronchopul-
monary dysplasia (BPD) was only associated with border-
line premature infants developing the respiratory distress 
syndrome (RDS) and using high airway pressures over the 
mechanical ventilation (MV) and elevated oxygen concen-
trations1. Since then, important information about neona-
tal care was acquired, but until today BPD remains as one 
of the major causes of morbidity and mortality in prema-
ture infants2-4. Mortality of premature infants has been re-
duced, however BPD incidence keeps elevated, as increas-
ingly premature infants survive and they have a higher 
risk for developing associated complications5,6. In Brazil, 
according to data obtained in 2001 from the Brazilian Net 
of Neonatal Research, BPD incidence ranges from 3.3% to 
30% for NBs with a birth weight lower than 1,500 g, with 
a mean of 18.4%; when only those with a birth weight be-
tween 500 and 750  g are considered, the estimated inci-
dence rises to around 70 to 85%7.
BPD pathophysiology is not fully understood yet, but it 
is a complex process in which there is a synergistic action 
of several factors on an immature body undergoing various 
insults and, at the same time, defense mechanisms are not 
fully developed4,8-10. Initial stimulus activating the inflam-
matory process may be the action of free radicals second-
arily to oxygen therapy, barotrauma, volutrauma, infectious 
agents, and other stimuli eliciting this disease in a still devel-
oping lung11,12. Prematurity and low birth weight are consid-
ered major risk factors for the disease and other factors have 
been observed recently, among which the patent ductus ar-
teriosus (PDA) could be mentioned13-15.
This study aims to review maternal and neonatal risk 
factors related to BPD development, as well as its inci-
dence among very low birth weight newborns admitted 
to a neonatal unit at Instituto de Medicine Integral Prof. 
Fernando Figueira (IMIP).
METHODS
This was a cross-sectional, retrospective and descriptive 
study involving the review of medical records in NBs with 
a very low birth weight admitted to the neonatal intensive 
care unit at IMIP. This is a tertiary facility whose neona-
tal unit receives high-risk newborns. The project has been 
approved by the Ethics and Research Committee in the 
mentioned hospital. All NBs with gestational age (GA) 
under 37 weeks and birth weight (BW) lower than 1,500 g 
were included over the period between June 2006 and De-
cember 2007. NBs carrying malformations, those dying 
within the first hours of life, those who were not on sup-
plemental oxygen during the hospitalization, and those 
whose required information was missing were excluded. 
Patent ductus arteriosus was not considered a congeni-
tal malformation, but rather a possible cardiocirculatory 
complication, in which a fetal pattern is maintained.
Based on the study inclusion criteria, a list of all NBs 
who could participate in the study (GA < 37 weeks and 
BW < 1,500 g) was requested to the IMIP Epidemiology 
Center. Data was collected through a survey and retro-
spective study of medical records, with the following in-
formation being extracted: birth weight, gestational age, 
gender, diagnostic hypotheses type of delivery, Apgar 
scores in the first and fifth minute, exogenous surfactant 
use, patent ductus arteriosus (PDA) diagnosed, days on 
invasive mechanical ventilation (IMV) and non-invasive 
mechanical ventilation (NIMV), days on supplemental 
oxygen and length of stay in the hospital.
Recorded gestational age was obtained via last men-
struation date (LMD); PDA was considered after clini-
cal suspicion was confirmed through echocardiography 
and BPD diagnosis was made in all NBs on supplemental 
oxygen with an inspired fraction higher than 21% for a 
period ≥ 28 days under any administration mode (IMV, 
NIMV or halo), following the 2000 Consensus Confer-
ence16.
The sample calculation used Epi Info 3.5.1 software 
and was performed aiming to estimate the BPD inci-
dence. The study target population consisted of 375 live-
born infants (number of subjects with a weight lower 
than 1,500 g and GA < 37 weeks, admitted to the neona-
tal unit between June 2006 and June 2007). Assuming a 
5% estimate error and an expected frequency of the event 
(BPD) of 20%, a sample size of 246 NBs was determined.
In the statistical analysis, Student’s t test was used 
to compare variables with a nearly normal distribution 
and Pearson’s chi-squared test was used to verify the ex-
istence of an association between categorical variables 
and the endpoint. In all tests, 5% significance level was 
adopted.
RESULTS
In this study, 454 eligible NBs were selected. Among 
them, 131 patients were excluded, 59 of them with 
malformations, 34 dying within the first six hours of 
life, 22 were not on supplemental oxygen over hospi-
talization, and 16 did not have the required informa-
tion; thus, the sample consisted of 323 NBs.
In the study sample, 48.9% (158/323) of NBs were 
male. Birth weight ranged from 590 to 1,490  g, with 
a mean of 1,161  ±  231  g. GA ranged from 24 to 36.5 
weeks, with a mean of 29.8  ±  2.4  weeks. C-section 
frequency was 49.5% (160/323). Apgar score at the 
first and fifth minute was higher than seven in 43.3% 
(140/323) and 89.2% (288/323) of the NBs, respec-
tively. Length of stay in the hospital ranged from 2 to 
124 days, with a mean of 44.8 ± 26.4 days. Among the 
study NBs, 96% had an initial diagnosis of RDS, 16.7% 
of transient tachypnea of the newborn (TTN), and 
30.3% of hypoxia.
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BPD
Yes No Total
PN n (%) n (%) n (%)
500-750 g 7 (43.8) 9 (56.2) 16 (100)
751-1.000 g 33 (42.3) 45 (57.7) 78 (100)
1.001-1.250 g 12(12.6) 83 (87.4) 95 (100)
1.251-1.499 g 5 (3.7) 129 (96.3) 134 (100)
Total 57 (17.6) 266 (82.4) 323 (100)
BPD, bronchopulmonary dysplasia; BW, birth weight.
Table 1 – Incidence of bronchopulmonary dysplasia according to the birth weight
Table 2 – Distribution of mean of days on ventilatory support among newborns with and without bronchopulmonary dysplasia
BPD
Yes No
Variable X ± SD X ± SD p
IMV (days) 17.6 ± 14.2 1.2 ± 3.0 < 0.001
NIMV (days) 16.2 ± 8.9 4.8 ± 4.4 < 0.001
Oxygen (days) 46.1 ± 15.5 9.0 ± 7.0 < 0.001
X, mean; SD, standard deviation; BPD, bronchopulmonary dysplasia; IMV, invasive mechanical ventilation; NIMV, non-invasive mechanical 
ventilation.
Student’s t-test.
BPD incidence in the study sample was 17.6%. NBs 
with 501 to 999 g were observed to have an incidence of 
44.7%, and it was 8% for birth weights between 1,000 and 
1,499 g when the newborns were analyzed according to the 
BW. The incidence of BPD can be better represented when 
the BW is stratified in more detail, as shown in Table 1.
Among NBs developing BPD, the mean of days on 
IMV, NIMV, and supplemental oxygen was 17.6, 16.2, and 
46.1 days, respectively, which is significantly higher than 
the mean of days on those supportive measures for NBs 
who did not develop the disease, as shown in Table 2.
BPD occurrence was significantly higher in NBs with a 
PDA diagnosis compared with those who did not experi-
ence this complication, as demonstrated in Table 3.
NBs with PDA and BPD diagnoses concomitantly 
had means of days on IMV, NIMV, supplemental oxygen 
and length of stay in the hospital of 18.6, 16.6, 44.8, and 
80.2  days, respectively, while in NBs who did not have 
the association with those complications the findings of 
2.3, 5.6, 11.9, and 40.4 days, respectively (p < 0.001) were 
shown.
Table 4 shows the association of NBs using exogenous 
surfactant with BPD incidence, with NBs on that therapy 
having higher incidence of the disease. However, NBs on 
exogenous surfactant were observed to have mean BW and 
GA significantly lower than those who did not receive the 
therapy, as described in Table 5.
Regarding the antenatal corticosteroid use and mater-
nal infection occurrence, no association with BPD inci-
dence was observed.
DISCUSSION
Because of the inconsistent definition of BPD, which 
makes the clinical diagnosis more difficult to establish, 
a great variability of the disease incidence was found 
in several neonatal care centers. Among preterm NBs, 
BPD incidence can range from 4% to 40%, according to 
a number of studies, being influenced by factors such 
as: study population characteristics, ventilation strategy 
and neonatal care routines5,9,12. BPD incidence, in the 
study sample, was 17.6%, representing values lower than 
those found by Tapia et al.10 who reported an incidence 
of 24.4%. In the study by Miguez et al.17, conducted from 
1997 through 2001, a BPD incidence of 12.5% was found.
As BPD has an incidence that is inversely related to 
the BW, we observed variations within our sample when 
different weight ranges were considered. When we com-
pared the incidence of BPD in NBs with a BW between 
500 g and 750 g with those with a BW between 751 g and 
1,000  g, no significant difference was found, but in the 
lower weight range, only 16 patients were noted, where-
as in the range between 751 g and 1,000 g, 78 NBs were 
found. For NBs in BW range from 1,251 to 1,499 g, BPD 
was seldomly seen.
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Table 3 – Association of newborns having patent ductus arteriosus with the incidence of bronchopulmonary dysplasia
BPD
PDA Yes No p
Yes 36 (63.2%) 21 (36.8%) < 0.001
No 21 (7.9%) 245 (92.1%) < 0.001
Total 57 (17.6%) 266 (82.4%) < 0.001
BPD, bronchopulmonary dysplasia; PDA, patent ductus arteriosus. 
Pearson’s chi-squared test.
Table 4 – Association between exogenous surfactant use and incidence of bronchopulmonary dysplasia
BPD
Surfactant Yes No Total p
Yes 46 (28.8%) 114 (71.2%) 160 < 0.001
No 11 (6.7%) 152 (93.3%) 163 < 0.001
Total 57 (17.7%) 266 (82.3%) 323 < 0.001
BPD, bronchopulmonary dysplasia.
Pearson’s chi-squared test.
Table 5 – Mean birth weight compared with gestational age, according with exogenous surfactant use
Surfactant use
Yes No
Variable n X ± SD n X ± SD p
BW(g) 160 1,064 ± 232 163 1,256 ± 186 < 0.001
GA (weeks) 160 28.7 ± 2.1 163 30.9 ± 2.1 < 0.001
X, mean; SD, standard deviation; BW, birth weight; GA, gestational age.
Pearson’s chi-squared test.
Fanaroff et al.18 reported an incidence of 23% among 
preterm NBs with a BW lower than 1,500  g at the Na-
tional Institute of Child Health and Human Development 
(NICHD), in the United States, over the period from 1997 
to 2002. The analysis of the sample stratified by BW range 
revealed that for NBs with a birth weight between 501 g 
and 750  g, the incidence was 57%; for those with a BW 
between 751 and 1,000 g, 32%; among those with a birth 
weight between 1,000 and 1,250 g, 14%, and for those be-
tween 1,251 and 1,500 g, only 6%.
Development of BPD is directly related to the time on 
mechanical ventilation and, according to Gonzaga et al.19, 
the possibility of a NB with a BW lower than 1,500 g to 
develop BPD is 11 times higher if it is kept on IMV for up 
to 14 days, with furtherly increased chances for those ven-
tilated for over 15 days, which shows extubation is an im-
portant feature whenever it is possible over the first week 
of life. In our study, we observed that among NBs develop-
ing BPD, the mean of days on both IMV and NIMV was 
always higher than 15 days, being significantly higher than 
the mean of days on those supports in NBs without this 
complication. Protective ventilatory strategies have been 
associated with a more favorable short- and long-term 
course in preterm NBs, with lower mortality and lower 
BPD incidence19,20. As yet, there is no consensus on the 
appropriate ventilatory support management to reduce 
the time on IMV and BPD incidence. Early use of a non-
invasive ventilatory support and maintenance of lower 
oxygen peripheral saturation levels are known to be as-
sociated with a lower risk for developing BPD20. Kobaly 
et al.21, when comparing their results from the years 2000 
and 2003, observed the implementation of new neonatal 
intensive care practices, such as antenatal corticosteroid, 
exogenous surfactant administration and appropriate 
PDA treatment produced better results, reducing the ab-
normalities found in skull ultrasonography and the me-
chanical ventilation dependence. Geary et al.22 found the 
early use of surfactant, followed by continuous positive 
airway pressure (nasal CPAP) with early inspired fractions 
of oxygen lower than 40% in the delivery room associated 
with early amino acid administration can reduce BPD in-
cidence and severity. Teixeira et al.23 observed marked as-
sociation between hyperoxia and BPD, reporting an arte-
rial blood partial pressure of oxygen (PaO2) higher than 
80 mmHg increased 3.42 times the newborns’ chance of 
developing BPD.
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Use of exogenous surfactant has been a valuable 
tool for modification of the classic BPD “new” DBP24. 
Surfactant replacement therapy in newborns with RDS 
improves lung function, leading to less need for high 
concentrations of oxygen and high pressures during me-
chanical ventilation, but is not effective in reducing the 
incidence of DBP24,25. In our study, we found asignificant 
association between use of exogenous surfactant and de-
velopment of BPD. This fact can be better understood 
when analyzed GA and BW of newborns, there is an in-
verse relationship between these variables and the devel-
opment of the disease.
Out of the 57 NBs with a PDA diagnosis in our sample, 
63.2% developed BPD. PDA is indicated as a major risk 
factor for BPD development, as it impacts the cardiopul-
monary system, with reduced lung compliance, increased 
pulmonary vascular resistance, often extending the IMV 
time. However, few studies show an association between 
this new risk factor and the disease. The association be-
tween PDA and BPD was observed to produce a significant 
increase in time on mechanical ventilatory support, oxy-
gen therapy and length of stay in the hospital, compared 
with NBs who did not have PDA and BPD concomitantly.
Behring et al.26 designed a predictive model trying to 
identify the probability of NBs progressing to BPD at the 
end of the first week of life and indicated PDA as one out of 
four more significant variables. For NBs with a gestational 
age less than 30 weeks, more than 2 days on mechanical 
ventilation, and over 15% BW loss up to the seventh day 
of life, PDA could raise the chances of the disease from 
76.5% to 93.7%.
Despite the association found between PDA and BPD, 
Schmidt et al.27 suggested in their studies that preventive 
treatment for PDA seems neither to reduce BPD incidence 
nor demonstrate a cause-effect relationship, that is, the 
presence of PDA increases the disease risk, but this risk 
is not changed when the prophylactic closure of a patent 
ductus arteriosus is performed.
In our study, we have found no association between 
maternal factors analyzed (antennal corticosteroid use and 
maternal infection) and BPD development, concurring 
with Rocha et al.28, despite their sample is quite vulner-
able, as it included NBs with a BW lower than 1,000 g and 
severe chorioamnionitis. However, although no significant 
association between maternal infection and BPD could be 
found, the presence of maternal infections can, according 
to a number of authors, induce a premature delivery, a ma-
jor impact factor on BPD development28,29.
Regarding antenatal corticosteroid use, no associa-
tion was found with a lower disease incidence, similarly to 
the findings by Tapia et al. and by the Brazilian Neonatal 
Research Network in 200430. This research suggests using 
antenatal corticosteroids promotes higher survival in pre-
term NBs, with an increased infection risk.
Van Marter et al.31 studied 193 NBs with a BW lower 
than 1,500  g with chorioamnionitis, mechanical ventila-
tion, and postnatal sepsis to better understand the in-
teraction between maternal infection and BPD and they 
observed extended mechanical ventilation and postnatal 
infection raised BPD risk among surviving premature 
NBs. Thus, these two factors interact with prenatal infec-
tion, further increasing the risk for developing the disease.
CONCLUSION
The incidence of BPD found in our sample is in line with 
the values reported in the literature and BW was a major 
risk factor for developing the disease, as the analysis of 
BPD incidence per weight range was found to be higher in 
those NBs with a lower birth weight. A long time on IMV, 
NIMV and oxygen therapy, as described in the literature, 
was associated with a higher incidence of the disease and 
the neonatal factor showing a strong correlation with BPD 
was PDA. Positive association of exogenous surfactant 
use and patent ductus arteriosus with BPD development 
demonstrated neonatal factors were determinant for the 
disease in the study sample. However, wider and deeper 
investigation with a higher number of subjects is warrant-
ed to elucidate as many associated factors as possible in 
order to elicit interventions increasingly early which can 
produce an impact on morbidity and mortality from this 
disease.
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